Strong Adjusted EBITDA Margin
Adjusted EBITDA for the third quarter was $518 million, representing a healthy margin of 32.3%, indicating strong operational efficiency despite headwinds.
Biosimilars Growth
Year-to-date performance driven by Hadlima, up 63% ex-FX globally, and an international tender for Ontruzant. The new denosumab biosimilar was approved and launched in the U.S.
Positive Free Cash Flow
Year-to-date, delivered $813 million of free cash flow before one-time costs, demonstrating strong cash generation capabilities.
Strategic Divestiture of Jada System
Organon entered into a definitive agreement to divest the Jada system for $440 million, plus an additional $25 million contingent on 2026 revenue targets, enhancing financial flexibility.